Amgen Inc. $AMGN Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.5% in the 1st quarter, Holdings Channel.com reports. The fund owned 626,393 shares of the medical research company’s stock after purchasing an additional 15,042 shares during the quarter. Principal Financial Group Inc.’s holdings in Amgen were worth $220,396,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Chicago Partners Investment Group LLC lifted its position in shares of Amgen by 12.1% during the first quarter. Chicago Partners Investment Group LLC now owns 6,559 shares of the medical research company’s stock worth $2,269,000 after purchasing an additional 710 shares during the last quarter. IFC Advisors LLC grew its stake in Amgen by 2.2% in the first quarter. IFC Advisors LLC now owns 2,751 shares of the medical research company’s stock worth $968,000 after purchasing an additional 58 shares in the last quarter. Global Assets Advisory LLC increased its holdings in Amgen by 6.9% in the first quarter. Global Assets Advisory LLC now owns 3,676 shares of the medical research company’s stock valued at $1,293,000 after buying an additional 238 shares during the last quarter. Trifecta Capital Advisors LLC increased its holdings in Amgen by 2.9% in the first quarter. Trifecta Capital Advisors LLC now owns 15,992 shares of the medical research company’s stock valued at $5,627,000 after buying an additional 458 shares during the last quarter. Finally, Valmark Advisers Inc. raised its stake in Amgen by 1.5% during the first quarter. Valmark Advisers Inc. now owns 8,726 shares of the medical research company’s stock valued at $3,070,000 after buying an additional 133 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $355.25 on Wednesday. The company has a market cap of $191.73 billion, a P/E ratio of 24.72, a PEG ratio of 3.56 and a beta of 0.41. The business has a 50 day moving average of $345.60 and a two-hundred day moving average of $349.81. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.31 EPS for the current year.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: BMO Capital reiterated its Buy rating on Amgen, reinforcing a bullish stance from one analyst firm. BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
• Positive Sentiment: One report argued Amgen could be as much as 47% undervalued after the Enbrel price-cap ruling, suggesting the stock may have meaningful upside if that view proves correct. Amgen (AMGN) Stock May Be 47% Undervalued After Enbrel Price Cap Ruling
• Neutral Sentiment: Amgen remains a heavily watched stock, and several articles focused on valuation comparisons and broader competitive positioning rather than a new company-specific catalyst. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Guggenheim raised its price target slightly to $343 while keeping a Neutral rating, signaling limited upside in the firm’s view. Amgen price target raised by Guggenheim
• Negative Sentiment: Bank of America Securities reiterated a Sell rating and said Amgen’s near-term growth remains limited, with the stock trading above its newly raised price target of $312. Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited

Analyst Ratings Changes

A number of research firms have commented on AMGN. BMO Capital Markets reaffirmed an “outperform” rating and set a $400.00 target price on shares of Amgen in a report on Wednesday, July 1st. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Morgan Stanley dropped their price target on Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. Truist Financial raised their price objective on Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $356.62.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.